Drugs / HR17031
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | type 2 diabetes mellitus | 2026-03-18 | “舒地胰岛素诺利糖肽注射液的药品上市申请获受理” hengrui.com ↗ “收到国家药监局下发的《受理通知书》” hengrui.com ↗ |
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06086912 | Nov → Dec 2023 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05292495 | Oct 2022 → Apr 2024 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05151705 | Dec 2021 → Jun 2022 | — | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05031871 | Sep → Nov 2021 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05333835 | Jul 2022 → Mar 2024 | type 2 diabetes mellitus | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06871761 | May 2024 → May 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT06881264 | Apr 2024 → Sep 2025 | — | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Jiangsu HengRui Medicine Co., Ltd. | Regulatory 恒瑞创新药舒地胰岛素诺利糖肽注射液用于成人2型糖尿病上市申请获受理 hengrui.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-03-18 | Jiangsu HengRui Medicine Co., Ltd. | 恒瑞创新药舒地胰岛素诺利糖肽注射液用于成人2型糖尿病上市申请获受理 hengrui.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HR17031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05333835 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT05292495 ↗ |